Celgene - Do you have Eosinophilic Esophagitis and difficulty swallowing?

Eosinophilic Esophagitis

Eosinophilic Esophagitis (EoE) is a chronic, allergic, inflammatory disorder of the oesophagus. EoE is usually caused by something in the diet, or something that has been inhaled, which triggers an allergic reaction resulting in swelling of the oesophagus. This inflammation usually results in difficulty swallowing. Other symptoms of EoE may include a feeling that food is stuck between the throat and stomach, chest pain, or upper abdominal pain. Additionally, a laboratory test will show a type of white blood cell, called an ‘eosinophil’, to be present in the oesophagus in large numbers, which is not normal.

The study treatment is called CC-93538 (also known as cendakimab). CC-93538 is an antibody, which is made in a laboratory and designed to stop the body’s immune system from triggering the allergic reaction.

The study evaluates the safety and effectiveness of CC-93538 for treatment of EoE and relief of swallowing difficulties.

Category
Trial Status
Active, not recruiting
Trial Phase
Phase 3 Drug Trial
Trial contact details
Contact Person
IBD Clinical Trials Unit
What you need to know

Who can take part?

  • Participants aged 12 -75
  • Body weight of ≥ 40 kg
  • Biopsy evidence of Eosinic Esophagitis
  • Difficulty swallowing
  • Must have had inadequate response to previous treatments
  • Willing to maintain stable diet
  • Willing to receive weekly injections

Exclusion

  • Participants with certain other diseases may be excluded from participating
  • Pregnant or breastfeeding women may not participate
  • Current infection
  • Immunosupression
  • Some medications may make you ineligible to participate

What is involced for you?

Participants will be randomly assigned to receive the investigational treatment or placebo in addition to standard medical care. They will also undergo the following tests and procedures:

  • Medical History and collection of demographic information
  • Vital signs
  • Electrocardiogram
  • Physical exam
  • Blood and urine tests
  • Pregnancy tests for women of childbearing potential
  • Endoscopy with esophagus tissue biopsy
  • Daily diary completion
  • Questionnaires
  • Weekly injections of treatmentor placebo

Trial dates

April 2022 to December 2023

All research clinical trials news

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.

29

Feb

Highlighting Mater Research’s year of achievements: 2023 Annual Report

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.

27

Oct

Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.

23

May

Mater launches trial of Australian-first flu vaccine

Displaying results 1-3 (of 18)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|